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In response to Martin et al:  
  
We agree with Martin et al that, as yet, late recurrence of hepatitis C following 
treatment has not been studied in this highly-exposed group of patients. To clarify 
the point made in our study “Next generation sequencing sheds light on the natural 
history of hepatitis C infection in patients that fail treatment”,(1) the majority of 
cases labelled as HCV reinfection within the 24 week window post-treatment are 
likely to represent viral rebound rather than reinfection, even in the presence of a 
switch in genotype or subtype.  In the absence of detailed sequencing data, it 
indeed seems likely that patients with recurrent HCV infection have a high rate of 
reinfection,(2) although there is a need to carry out an appropriately designed 
study to confirm this as some studies in other highly exposed cohorts have shown 
that relapse is associated with recrudescence of similar strains, others have lacked 
analysis of paired samples and none have employed a next generation sequencing 
approach.(3, 4)  In the meantime, the proposed adjustment to the reinfection rate 
following removal of the 7% of patients that relapsed within the 24 week post-
treatment would seem entirely appropriate.(5, 6)  We also agree that retreatment 
is indicated in patients with recurrent HCV infection.  The role of the emergence 
of resistant variants will be of particular interest as DAAs are rolled out, in 
particular when interferon-free regimens are used, as interferon resistance is 
likely to be heavily influenced by the host response and is unlikely to occur solely 
due to mutations within the viral genome.  
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